AGT and triple-A syndrome: To determine whether overexpression of miR-19b-3p in AMEXO could improve the therapeutic effects on AAA, Ang II-induced AAA mice were intravenously injected with AMEXO and miR-19b-3p-AMEXO every 3 days starting the day following Ang II infusion, and aortic tissue collected after 28 days (Figure S2).